.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Farmers Insurance
Boehringer Ingelheim
Baxter
Fish and Richardson
Daiichi Sankyo
Fuji
Mallinckrodt
US Department of Justice

Generated: December 15, 2017

DrugPatentWatch Database Preview

Acorda Company Profile

« Back to Dashboard

What is the competitive landscape for ACORDA, and what generic alternatives to ACORDA drugs are available?

ACORDA has four approved drugs.

There are six US patents protecting ACORDA drugs.

There are sixty patent family members on ACORDA drugs in twenty-three countries and twenty-two supplementary protection certificates in nine countries.

Summary for Acorda

International Patents:60
US Patents:6
Tradenames:3
Ingredients:3
NDAs:4
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
AcordaZANAFLEXtizanidine hydrochlorideTABLET;ORAL020397-001Nov 27, 1996ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
AcordaAMPYRAdalfampridineTABLET, EXTENDED RELEASE;ORAL022250-001Jan 22, 2010ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
AcordaAMPYRAdalfampridineTABLET, EXTENDED RELEASE;ORAL022250-001Jan 22, 2010ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
AcordaZANAFLEXtizanidine hydrochlorideCAPSULE;ORAL021447-001Aug 29, 2002ABRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
AcordaAMPYRAdalfampridineTABLET, EXTENDED RELEASE;ORAL022250-001Jan 22, 2010ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
AcordaAMPYRAdalfampridineTABLET, EXTENDED RELEASE;ORAL022250-001Jan 22, 2010ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
AcordaZANAFLEXtizanidine hydrochlorideCAPSULE;ORAL021447-003Aug 29, 2002ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
AcordaQUTENZAcapsaicinPATCH;TOPICAL022395-001Nov 16, 2009RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
AcordaAMPYRAdalfampridineTABLET, EXTENDED RELEASE;ORAL022250-001Jan 22, 2010ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
AcordaAMPYRAdalfampridineTABLET, EXTENDED RELEASE;ORAL022250-001Jan 22, 2010ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Acorda

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
AcordaAMPYRAdalfampridineTABLET, EXTENDED RELEASE;ORAL022250-001Jan 22, 2010► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for ACORDA drugs

Drugname Dosage Strength Tradename Submissiondate
dalfampridineExtended-release Tablets10 mgAMPYRA1/22/2014
tizanidine hydrochlorideCapsules2 mg, 4 mg and 6 mgZANAFLEX8/10/2007

Non-Orange Book Patents for Acorda

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,370,879 Formulations and their use in the treatment of neurological diseases► Subscribe
6,248,788 Therapeutic method with capsaicin and capasicin analogs► Subscribe
5,580,580 Formulations and their use in the treatment of neurological diseases► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Acorda Drugs

Country Document Number Estimated Expiration
European Patent Office2460521► Subscribe
European Patent Office2377536► Subscribe
Portugal2377536► Subscribe
Japan5736100► Subscribe
Japan2015057451► Subscribe
Spain2141706► Subscribe
Hungary913447► Subscribe
Japan2012188427► Subscribe
Austria344023► Subscribe
European Patent Office0484186► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Acorda Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2013015Lithuania► SubscribePRODUCT NAME: FAMPRIDINUM; REGISTRATION NO/DATE: EU/1/11/699/001 - EU/1/11/699/002 20110720
2013 00045Denmark► Subscribe
0120002 00051Estonia► SubscribePRODUCT NAME: FAMPYRA - FAMPRIDINE;REG NO/DATE: C(2011)5390 FINAL 20.07.2011
00515Netherlands► SubscribePRODUCT NAME: FAMPRIDINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT; REGISTRATION NO/DATE: EU/1/11/699/001-002 20110720
00503Netherlands► SubscribePRODUCT NAME: 4-AMINOPYRIDINE EN DERIVATEN DAARVAN; REGISTRATION NO/DATE: EU/1/11/699/001-002 20110720
275Luxembourg► SubscribePRODUCT NAME: 4-AMINOPYRIDINE OU UN DERIVE DE CELUI-CI, SPECIALEMENT UN SEL, UN SOLVANT OU UNE PRODROGUE; FIRST REGISTRATION: 20110720
2013015,C2377536Lithuania► SubscribePRODUCT NAME: FAMPRIDINUM; REGISTRATION NO/DATE: EU/1/11/699/001 - EU/1/11/699/002 20110720
2012 00004Denmark► Subscribe
C0033France► SubscribePRODUCT NAME: FAMPRIDINE OU L'UN DE SES DERIVES; REGISTRATION NO/DATE: EU/1/11/699/001-002 20110725
00612Netherlands► SubscribePRODUCT NAME: 4-AMINOPYRIDINE, DAN WEL EEN DERIVAAT DAARVAN, IN HET BIJZONDER EEN ZOUT, SOLVAAT OF PRODRUG; REGISTRATION NO/DATE: EU/1/11/699/001-002 20110720
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Queensland Health
Accenture
UBS
Novartis
McKesson
Farmers Insurance
Dow
QuintilesIMS
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot